Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Other Accumulated Expenses (2022 - 2025)

Capricor Therapeutics (CAPR) has 4 years of Other Accumulated Expenses data on record, last reported at $2.6 million in Q3 2025.

  • For Q3 2025, Other Accumulated Expenses rose 26121.55% year-over-year to $2.6 million; the TTM value through Sep 2025 reached $2.6 million, up 26121.55%, while the annual FY2024 figure was $435712.0, 4257.12% up from the prior year.
  • Other Accumulated Expenses reached $2.6 million in Q3 2025 per CAPR's latest filing, up from $1.4 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $2.6 million in Q3 2025 and bottomed at $10000.0 in Q4 2023.
  • Average Other Accumulated Expenses over 4 years is $485865.9, with a median of $54706.0 recorded in 2022.
  • Peak YoY movement for Other Accumulated Expenses: plummeted 88.79% in 2023, then soared 26121.55% in 2025.
  • A 4-year view of Other Accumulated Expenses shows it stood at $89234.0 in 2022, then tumbled by 88.79% to $10000.0 in 2023, then skyrocketed by 4257.12% to $435712.0 in 2024, then surged by 501.81% to $2.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $2.6 million in Q3 2025, $1.4 million in Q2 2025, and $201681.0 in Q1 2025.